Cardiovascular disease

Red blood cells
#Cardiovascular disease #Clinical trials #Drug development

Baxdrostat offers hope for stubborn high blood pressure 

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high despite medication, according to the results of a Phase III clinical trial.  The international BaxHTN trial, led by Professor Bryan Williams, UCL Institute of Cardiovascular Science, and sponsored by… Read More

#News

Mounjaro
#Cardiovascular disease #Diabetes #Eli Lilly #GLP-1 #Obesity

Mounjaro comes out on top in head-to-head trial

Lilly has shared topline results from SURPASS-CVOT, a head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.   Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed… Read More

#News

chronic obstructive pulmonary disease
#Cardiovascular disease #Chronic obstructive pulmonary disease (COPD) #Merck #Mergers and acquisitions

Merck acquires Verona, expands cardio-pulmonary portfolio

Merck (known as MSD outside of the US and Canada) is to acquire Verona Pharma for a total transaction value of approximately $10 billion.  Through this acquisition Merck will add Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline… Read More

#Business & Investment #News

Human heart
#Cardiovascular disease #Cell therapy #Longeveron #Paediatrics #Phase II trial #Regenerative Medicine

Regenerative cell therapy for rare heart disease enters PhII trials

Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS).  Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications.  Top-line trial results are anticipated in… Read More

#News

Patient using blood pressure monitor
#Cardiovascular disease #Collaboration #Novartis #ProFound Therapeutics

Novartis and ProFound agree cardiovascular collaboration

Novartis and ProFound Therapeutics have announced a four-year collaboration to discover and develop novel therapeutics for cardiovascular disease.  The collaboration will join ProFound’s capabilities in the identification of novel proteins from the expanded proteome as drugs and drug targets with Novartis’ cardiovascular drug development expertise.  ProFound’s ProFoundry Platform combines multi-layered… Read More

#Business & Investment #News

#Antibiotics #Cardiovascular disease #University of Bath #University of Cape Town

Surprising new role discovered for commonly-used antibiotic

Scientists from the UK and South Africa have discovered a surprising new role for a commonly-used antibiotic that could open the door to a new family of improved therapies for high blood pressure and cardiovascular disease.  The international team, led by Professor Ravi Acharya from the University… Read More

#Editor's Choice #News

Human heart
#Bayer #Cardiovascular disease #Heart failure #MHRA

UK authorises Bayer’s acoramidis for transthyretin amyloidosis

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of Beyonttra (acoramidis) in the UK for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).  ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart… Read More

#News #Regulatory

Heart attack patient with doctor
#Cardiovascular disease #Cholesterol #Heart attack #Imperial College London #Lund University #Statins

Statins and ezetimibe combination could prevent heart attacks

A new study from researchers at Lund University in Sweden and Imperial College London suggests that treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks.  For those who survive a heart attack, the risk of a… Read More

#News

Cholesterol test
#AstraZeneca #Cardiovascular disease #Cholesterol #Clinical trial

PCSK9 inhibitor demonstrates significant cholesterol reduction

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 have demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy.  AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite… Read More

#News

Heart monitor
#Cardiovascular disease #Chronic kidney disease (CKD) #Diabetes #GLP-1 #Novo Nordisk #Weight loss

Oral semaglutide reduces risk of cardiovascular events

The results of the SOUL cardiovascular outcomes trial have demonstrated that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).   The new data were featured during a late-breaking clinical… Read More

#News

#Cardiovascular disease #Closed Loop Medicine #GLP-1 #US patent

Closed Loop Medicine secures US patents for GLP-1 therapies

Closed Loop Medicine has been granted US patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.  The company currently holds over 65 filings across 16 patent families.   In the rapidly-established GLP-1 market, the company’s IP covers dose optimisation according to patient-specific… Read More

#Business & Investment #News

#Cardiovascular disease #European Innovation Council #Investment #VarmX

VarmX awarded €15m by the European Innovation Council

VarmX has been awarded a follow-on equity investment of €15 million from the European Innovation Council (EIC) Accelerator.   The company is working to develop innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.  The funds received from the investment will… Read More

#Business & Investment #News

Novartis head office
#Anthos Therapeutics #Cardiovascular disease #Mergers and acquisitions #Monoclonal antibodies #Novartis

Novartis acquires Anthos Therapeutics for $925 million

Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway.  Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation.  Novartis will make an… Read More

#Business & Investment #News #Trending News

Human heart
#Cardiovascular disease #Gene therapy #Phase II trial #XyloCor Therapeutics

XyloCor financing advances one-time cardiovascular gene therapy

XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina.  The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter.   The financing will also fund a Phase II trial… Read More

#Business & Investment #News

Heart monitor
#BridgeBio Pharma #Cardiovascular disease #FDA #Phase III trial

FDA approves Attruby to reduce cardio death in ATTR-CM patients

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), a near-complete (≥90%) stabiliser of Transthyretin (TTR).  It is approved for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalisation.   The FDA approval is based on the ATTRibute-CM Phase III… Read More

#News #Regulatory

Human heart
#Cardiovascular disease #Heart disease #Phase II trial #RNA #Silence Therapeutics

Silence Therapeutics presents late-breaking Phase II data at AHA

Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels. These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific… Read More

#News